Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Clinical trial NCT04955743 · TERMINATED

Trial details

NCT number: NCT04955743
Sponsor: Yale University
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma Renal Cell Carcinoma Brain Metastases PD1/PD-L1 Experienced Pembrolizumab Lenvatinib Metastatic Melanoma

Start date: 2022-02-09
Primary completion: 2025-05-28
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.